$CRIS News

HC Wainwright & Co. Reiterates Buy on Curis, Maintains $43 Price Target

Curis (CRIS) Stock Fair Value Moves Lower After Emavusertib TakeAim Model Rework

Curis Doses First Five Patients in TakeAim CLL Study

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus

HC Wainwright & Co. Maintains Buy on Curis, Raises Price Target to $43

Curis (CRIS) Stock Sees Fair Value Lift As Analysts Back Leadership And Consumer Focus

Curis, Inc. (CRIS) Discusses Positive Data From Emavusertib Combination Study in Primary CNS Lymphoma Transcript

Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates

Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS)

Curis Announces Positive Emavusertib Update

Curis Consents First Six Patients in TakeAim CLL Study

Curis Announces It Has Consented The First Six Patients In The TakeAim CLL Study

Why Did Curis (CRIS) Stock Soar After Hours?

Curis opens 11 sites for emavusertib combo in TakeAim CLL trial

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Curis Shareholders Approve Reverse Stock Split Effect Ratio From 1-For-5 To 1-For-25

Curis (CRIS) Q1 2026 Earnings Call Transcript

Curis, Inc. Q1 2026 Earnings Call Summary

Curis Inc (CRIS) Q1 2026 Earnings Call Highlights: Progress in Lymphoma Study and Financial ...